| Similar Articles |
|---|
 |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.   |
The Motley Fool
February 22, 2005
Rich Duprey |
Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%. |
The Motley Fool
February 17, 2011
Brian Orelli |
Nice Deal, Now Let's See Some Data AVEO Pharmaceuticals struck a solid partnership with Astellas Pharma and its investors are rewarding the company today. |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
Pharmaceutical Executive
January 1, 2009
Walter Armstrong |
Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges. |
Pharmaceutical Executive
July 3, 2007 |
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
Pharmaceutical Executive
January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Pharmaceutical Executive
January 1, 2007
Walter Armstrong |
Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy. |
Pharmaceutical Executive
July 1, 2013
Looney et al. |
Pharm Exec's 2013 Emerging Pharma Leaders Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what? |
The Motley Fool
July 27, 2011
Brian Orelli |
Switching Partners Provides a Big Shot in the Arm Merck loves Cardiome more than Astellas does. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
Pharmaceutical Executive
May 1, 2007 |
Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Pharmaceutical Executive
September 1, 2008
Walter Armstrong |
The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
The Motley Fool
May 23, 2006
Rich Duprey |
Eisai Has a Yen for Profits With new formulations for its current drugs planned for release, expansion of its blockbuster drug Aricept possible, and with a few new drugs in the pipeline, the Japanese pharmaceutical is poised to continue churning out record revenues and earnings that investors won't soon forget. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
February 4, 2010
Brian Orelli |
A Drugless Drugmaker IPO! Biotech investors embrace risk ... sort of. The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
Pharmaceutical Executive
January 1, 2007
Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Biotech Prospects for a Sizzling Summer Consider these biotech stocks to make your portfolio sizzle this summer. Advanced Life Sciences... Depomed... Theravance... etc. |
The Motley Fool
March 12, 2009
Brian Orelli |
2 Suitors Are Better Than 1 Recent drug company acquisitions prove that competition benefits shareholders. |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
Pharmaceutical Executive
December 1, 2008
Patrick Clinton |
Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry. |
The Motley Fool
January 3, 2012
Brian Orelli |
High Expectations Trump Solid Results AVEO slumps despite solid results for tivozanib. |
Bio-IT World
Dec 2006/Jan 2007
Deborah Borfitz |
Rave Review for Medidata's Asian EDC Advantage Tokyo-based Astellas Pharma will use Medidata's Rave 5.5 for all its global clinical studies over the next five years. Another new biopharma customer for Rave is AstraZeneca. |
The Motley Fool
January 28, 2009
Brian Orelli |
M&A Off the Beaten Path CV Theraputics gets courted. |
The Motley Fool
July 15, 2011
Brian Orelli |
Vical Transplants Some Firepower A licensing deal with Astellas gives the company a shot in the arm. |
Entrepreneur
September 2006
Chris Penttila |
Back in Business Japan's economy is picking up. Should your company explore the possibilities? |
Pharmaceutical Executive
November 1, 2014
Jill Wechsler |
Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge. |
Financial Planning
June 1, 2010
Donald Jay Korn |
Rediscovering Japan After 20 years of feast and 20 years of famine, is it time for investors to put Japanese stocks back on the menu? |
Investment Advisor
May 1, 2011
Savita Iyer-Ahrestani |
Shared Sorrow, Shared Strength: Rebuilding Japan Japan's string of disasters will demonstrate the unyielding strength of the people and the country's opportunity for growth |
IndustryWeek
February 15, 2012
Jonathan Katz |
Trade Wars: Could Lessons Learned From Japan in the 1980s Apply to China Today? Japan Inc. didn't kill U.S. manufacturing, but did the United States learn from that competitive era? |
Pharmaceutical Executive
February 1, 2006
Chandler & Chicco |
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways |
The Motley Fool
August 9, 2010
Brian Orelli |
Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble." |
Pharmaceutical Executive
August 1, 2011
Bill Drummy |
The Slow Dance Toward Obsolescence Does Big Pharma have the emotional connection and intellectual commitment to move with the pace of change? |
The Motley Fool
April 14, 2008
Brian Lawler |
A Little Delay Goes Away for CVT CV Therapeutics can move ahead, now that it has won marketing approval for its cardiac stress agent regadenoson. |
The Motley Fool
April 17, 2008
Brian Lawler |
CVT's Copacetic Cash Management Drugmaker CV Therapeutics signs away a little portion of its royalty stream from a recently approved drug, in order to get a lot back. |
Real Travel Adventures
May 2007
Robert A. Kendrick |
When Traveling In Europe, Follow the Rising Sun When running into a Japanese tour bus in Europe, don't be annoyed. Rather realize that their presence indicates that you are at a sight worth seeing. |
